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LABORATORY STUDY
Inhibitors of the renin-angiotensin system ameliorates clinical and
pathological aspects of experimentally induced nephrotoxic serum nephritis
M. E. Ougaarda,b , H. E. Jensenb, I. D. Thuenb, E. G. Petersenb and P. H. Kvista
aHaemophilia PK & ADME, Novo Nordisk, Frederiksberg, Denmark; bDepartment of Veterinary Disease Biology, University of
Copenhagen, Frederiksberg, Denmark
ABSTRACT
Introduction: Chronic kidney disease (CKD) is a global health concern, but the current treat-
ments only slow down the progression. Thus an improved understanding of the pathogenesis
and novel treatments of CKD are needed. The nephrotoxic nephritis (NTN) model has the poten-
tial to study the pathogenesis of CKD as it resembles human CKD. The classical treatments with
angiotensin II receptor blocker (ARB) or the angiotensin-converting enzyme inhibitor (ACE I) have
shown a clinical effect in CKD.
Methods: We characterized the disease development in the NTN model over 11weeks by
investigating functional and histopathological changes. We tested doses of 15 and 30mg/kg/day
enalapril and losartan in the NTN model in order to investigate the effect of inhibiting the renin-
angiotensin-system (RAS).
Results: The NTN model displayed albuminuria peaking on days 6–7, mesangial expansion (ME),
renal fibrosis, inflammation and iron accumulation peaking on day 42. However, albuminuria, ME,
renal fibrosis and inflammation were still significantly present on day 77, suggesting that the
NTN model is useful for studying both the acute and chronic disease phases. Enalapril and losar-
tan significantly enhanced the glomerular filtration rate (GFR) and decreased albuminuria, ME,
renal fibrosis and inflammation of NTN-induced kidney disease in mice.
Conclusions: This is the first study showing a comprehensive pathological description of the
chronic features of the murine NTN model and that inhibiting the RAS pathway show a signifi-
cant effect on functional and morphological parameters.
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Introduction
Chronic kidney disease (CKD) is characterized by a pro-
gressive decline in kidney function, renal inflammation
and fibrosis that eventually affects the whole kidney with
the final consequence of end-stage renal disease [1].
Various animal models have been established in order to
understand the pathogenesis of CKD. The NTN model is a
well-known model of acute glomerulonephritis, but it
also resembles the chronic stages of CKD [2]. Another
advantage is that the model is easy to induce as it is a
non-surgical and non-transgenic model. Despite that the
NTN model has been utilized for several decades, the
knowledge is limited of the disease progression over
time regarding clinical and pathological changes, beyond
the classical study timeframe of 3–6weeks [3,4].
A common target of classical treatments of CKD is
angiotensin II (Ang II). Intrarenal Ang II regulates the
blood pressure by causing vasoconstriction and increas-
ing aldosterone secretion which stimulates the
reabsorption of water and sodium [5]. Moreover, in kid-
ney disease, the activation of the renin-angiotensin-sys-
tem (RAS) and its key player Ang II induces recruitment
of renal infiltrating inflammatory cells [6]. The Ang II
receptor blockers (ARBs) and the angiotensin-convert-
ing enzyme inhibitors (ACE I’s) both ameliorate CKD
and their use is recommended as first-line agents in
diabetic and non-diabetic renal disease with albumin-
uria by the National Kidney Foundation [7]. However,
treatment with ACE I’s and ARB’s only slow down the
progression of CKD [7]. Thus improved understanding
of the pathogenesis and improved treatments of CKD
are warranted. Furthermore, there is limited knowledge
of whether and how RAS plays an important role in the
pathogenesis of the NTN model. Therefore, we
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conducted an 11 weeks’ time-course study to character-
ize the NTN model and to identify the optimal time-
frame showing a clear difference between NTN and
control mice. The characterization was focused on clin-
ical and pathological changes including the morphology,
mesangial expansion (ME), glomerular basal membrane
(GBM) thickening, renal fibrosis, iron and complement
accumulation, proliferating of renal cells and infiltration
of inflammatory cells. Secondly, we conducted a treat-
ment study with an ACE-i (enalapril) and an ARB (losar-
tan) to investigate whether RAS plays a pathogenic role
in the NTN model and to identify a clinically relevant
positive control for CKD treatment studies in the NTN
model. The doses were based on previously published
studies treating CKD mice with enalapril or losartan
[8–10]. The treatment effect on the pathogenesis was
investigated by evaluating several histopathological end-
points and the highly relevant parameter of kidney func-
tion; the glomerular filtration rate (GFR).
Methods
In vivo studies
Twelve-weeks old CD1 mice (Charles River, Germany)
were housed in a facility with a 12 h light/dark cycle. All
animal experiments were approved by the Danish
Animal Inspectorate and the Novo Nordisk ethical
review board. Passive NTN was induced by tail-vein
injection of 50 ll of sheep anti-rat NTS (Probetex, San
Antonio, USA, PTX-001S lot#199-8) for three consecu-
tive days. Control mice received PBS in a similar man-
ner. The study design followed a randomized block
design with 40 mice in each group. At days 7, 42, 63
and 77 ten mice per group were sacrificed, and plasma
and kidneys were collected. Prior to termination, mice
were induced with isoflurane and the kidneys were per-
fused with 0.9% NaCl with Heparin (10U/ml).
The treatment study was conducted similarly, but
the timeframe was 42 days. The study included 6
groups consisting of a vehicle group (only NTS, n¼ 8),
two enalapril groups (15 or 30mg/kg/day), two losartan
groups (15 or 30mg/kg/day, n¼ 8 and 8, respectively),
and a healthy control group (n¼ 8). During the acclima-
tization the fluid intake of the mice was measured to
calculate the doses of enalapril and losartan as it was
administrated via their drinking water. The doses were
calculated based on water intake and body weight.
Urine and plasma analysis
Urine samples were collected by metabolic caging for
18h on days 6–7, 34–35, and 62–63 and on days 7–8,
and 36–37 in the treatment study. The urinary albumin
concentration was measured by ELISA (Bethyl
Laboratories, cat.no. E90-134) and the 24h urinary albu-
min excretion rate (UAER) was calculated. The urinary
creatinine was measured by a COBAS 8000 analyser
ande the albumin creatinine ratio (ACR) was calculated.
Blood samples were collected on days 7, 42, 63, and 77
in the time course study and on days 13 and 42 in the
treatment study. Renin plasma concentration was meas-
ured by ELISA (R&D systems, Minneapolis Cat.no DY008).
Glomerular filtration rate
The glomerular filtration rate (GFR) was measured by a
preclinical transdermal GFR monitor (Medibeacon
GmBH, Mannheim, Germany) as previously described
[11]. In short, two times two centimeters fur on the
back of the mice were depilated 24 h prior to GFR
measurements. FITC-sinistrin (Medibeacon GmBH,
Mannheim, Germany) was dissolved in physiological
saline, and a stock of 15mg/ml was prepared and
stored at –20 C away from light. Mice were shortly
anesthetized while the GFR monitor was adhered to the
depilated area. Subsequently, the mice were injected
with 7.5mg/100g BW of FITC-sinistrin intravenously into
the tail vein. The mice were placed for one hour in a
single-cage. Afterward the tape was removed and the
GFR data were transferred and GFR was calculated.
Histological analysis
The kidneys were fixed in 10% neutral formalin buffer
for 30 h, processed by standard procedures and
embedded in paraffin.
Scoring of the morphological changes including ME,
GBM thickening, metaplasia, hyaline droplets and pro-
tein casts as described in Supplementary materials.
H&E and Perls Prussian Blue staining were performed
following the standard procedure. Sheep anti-GBM
immunohistochemical (IHC) staining is described in
Supplementary materials.
Immunohistochemical characterization of
proliferation, fibrosis, inflammation and
complement deposition
All IHC stainings are described in Supplementary mate-
rials, Table 1.
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Digital image analysis for quantification of Ki-67,
Perl, collagen III, CD45, CD3, F4/80 and C3d
The slides were scanned by a Nanozoomer 2.0 (20).
The image analysis was performed using Visiopharm
Integrator System (VIS; Visiopharm, Denmark). An auto-
mated tissue detection protocol was performed as pre-
viously published [12]. Quantification of collagen III,
CD45, CD3, F4/80 and C3d was determined in a region
of interest (ROI) restricted to the kidney cortex. Within
the ROI, a threshold analysis was performed using an
HDAB-DAB filter (1 - 140) (Ki-67), Haematoxylin (1 -
140) (Perl) or a red-green filter (30–170) (collagen III,
CD45, CD3, F4/80 and C3d) as previously pub-
lished [12].
Statistics
Statistical analyses were performed using GraphPad
Prism (v7.03; GraphPad, CA), and data were presented
as mean± standard deviation (SD). D’Agistino-Pearson
and Shapiro–Wilk normality tests were performed.
Normally distributed data were analyzed by one-way
ANOVA multiple testing with Turkey’s correction, and
non-normally distributed data were analyzed using
Kruskal–Wallis multiple testing with Dunn’s correction.
A p value <.05 was accepted as significant.
Results
A time course evaluation of clinical measurements
of the passive NTN model
At baseline, both the NTN and control mice on average
weighed 32 g. After 11weeks the NTN mice weighed on
average 2 g more than the control mice (Figure 1(A))
and did not show compromised health during
the 11weeks.
The NTN mice developed significantly increased urin-
ary albumin excretion rate (UAER) which peaked on
days 6–7, but the UAER remained significantly increased
until days 62–63 compared to their healthy controls
(Figure 1(B)).
A time course evaluation of morphological
changes in the passive NTN model
Antibodies (NTS) (Supplementary materials, Figure 1)
were present in all glomeruli and the majority of glo-
meruli were focally or diffusely enlarged, and intra- and
periglomerular infiltration of inflammatory cells was
seen at day-7 (Figure 3). At this early stage of the dis-
ease, both tubular and glomerular cells proliferate
(Figure 2(C–D)), but the glomerular complement depos-
ition (Figure 3(D)) and ME was modest (Table 1 and
Figure 3(E)), and tubular changes (Table 1) together
with fibrosis were mild or infrequently observed
(Figures 2(B) and 3(E)). The hypercellularity of glomeruli
had increased significantly at day-42 due to the prolifer-
ation of mesangial cells and infiltration of inflammatory
cells consisting of neutrophils, macrophages and lym-
phocytes. There was clear glomerular complement
deposition (Figure 3(D,E)) and thickening of the GBM,
globally sclerotized glomeruli and some crescent forma-
tion in contrast to day-7 (Table 1). Tubular changes
were observed focally and characterized by tubular
atrophy, i.e., a curvy basal membrane, peritubular infil-
tration of inflammatory cells, focal tubular casts and
PAS-positive intratubular vesicles were observed (Table
1). Iron accumulation had developed at day-42 whereas
none was observed at day-7 (Figures 2(A) and 3(E)). The
fibrotic changes were significantly increased and
located both intra- and extraglomerularly (Figures 2(B)
and 3(E)). From day-42, the general histopathological
changes seem to decrease but a ME, inflammation and
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Figure 1. A time course evaluation of clinical measurements of the passive NTN model. (A) XY plot showing body weight (BW)
over time. (B) XY plot showing the urinary albumin excretion rate (UAER). Data are shown as mean ± SD. p< .001,p< .0001, NTN group vs. healthy control group by one-way ANOVA.
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fibrosis were evident in and around glomeruli and
tubuli (Table 1, Figures 2 and 3).
Inhibitors of RAS restores the glomerular filtration
rate and ameliorates the renal damage
Based on the chronic NTN model in the 77 days study it
was concluded that clinical and morphological parame-
ters differed mostly at day-42, therefore, the treatment
study with inhibitors of the RAS system was then per-
formed for 42 days. The bodyweight measurements
throughout the study showed that neither enalapril nor
losartan caused any weight loss in the treated mice
(Table 2). The kidney function was evaluated by meas-
uring albuminuria and the GFR. Enalapril and losartan
treatment (15 and 30mg/kg/day) showed significantly
reduced albumin concentration and UAER on days 7–8
and 36–37 compared to the vehicle group. Doses of
30mg/kg/day of losartan showed a significantly
improved effect on the UAER compared to 15mg/kg/
day losartan on day 7–8 (19.1 ± 15.0 and 38.0 ± 22.7
(mg/ml), respectively). Both enalapril and losartan
(30mg/kg/day) reduced the ACR to baseline (Table 2).
The GFR measurements on days 38–40 showed an
effect of treatment with 30mg/kg/day enalapril and los-
artan (Figure 4). The effect on the negative feedback
action of angiotensin II on renin production was investi-
gated by measuring plasma renin concentrations.
Enalapril treatment caused significantly increased
plasma renin concentrations which increased over time
and losartan-treated mice showed a tendency towards
increased plasma renin concentration on days 13 and
42 compared to the vehicle mice (Table 2).
The 15 and 30mg/kg/day enalapril groups showed a
significant reduction in the mean ME score compared
to the vehicle group. Interestingly, only the 30mg/kg/
day losartan group showed reduced ME compared to
the vehicle group (Figure 5(A,E)). Doses of 15 and
30mg/kg/day of enalapril and losartan reduced the
renal accumulation of collagen III on day 42 (Figure
5(B,E)). Furthermore, 15 and 30mg/kg/day enalapril and
losartan reduced the level of infiltration by leukocytes
(Figure 5(C,E)). Neither enalapril nor losartan treatment
had a significant effect on complement C3d deposition
when analyzing glomeruli separately or the whole kid-
ney (Figure 5(D,E)).
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Figure 2. A time course evaluation of morphological changes in the passive NTN model. (A) Scatter plot is showing semi-quanti-
fication of Perl positive area in the cortex area. (B) Scatter plot is showing semi-quantification of Collagen III positive area in the
cortex area. (C) Scatter plot is showing semi-quantification of the Ki-67 positive area in the cortex area. (D) Representative images
are showing the Ki-67 positive area in the cortex area. Data are shown as mean ± SD. p< .01, p< .0001 NTN groups vs.
healthy control groups and, #p< .05, ##p< .01, ###p< .001 ####p< .0001 NTN group vs. NTN group by one-way ANOVA using
Tukey’s multiple comparisons test (n¼ 10).
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Discussion
The 11 weeks’ time course study was performed to
characterize the disease development in detail in acute
and chronic settings and to identify the optimal time
frame where disease parameters differ the most
between diseased and control mice; enabling the opti-
mal point in time for identification of treatment effects
in the NTN model. We found that the NTN model
Table 2 The effect of inhibitors of the renin-angiotensin system on clinical data including body weight (BW), albumin concentra-
tion, urinary albumin excretion rate (UAER), and renin plasma concentration data are shown as mean ± SD.
Groups Vehicle Healthy ctrls Enalapril Enalapril Losartan Losartan
N = 10 N = 10 15mg/kg N = 10 30mg/kg N = 10 15mg/kg N = 10 30mg/kg N = 10
Bodyweight (g) Start Start Start Start Start Start
31.2 ± 2.4 31.3 ± 1.8 31.3 ± 2.3 30.8 ± 1.4 30.2 ± 1.4 31.3 ± 0.9
End End End End End End
33.1 ± 2.7 34.3 ± 2.9 33.5 ± 2.6 32.5 ± 2.2 32.9 ± 1.7 33.7 ± 1.7
Albumin (mg/ml) Day 7–8 Day 7–8**** Day 7–8*** Day 7–8**** Day 7–8* Day 7–8****
30.3 ± 10.4 0.04 ± 0.03 11.8 ± 8.8 8.9 ± 8.8 18.2 ± 9.8 9.9 ± 5.5
Day 36–37 Day 36–37**** Day 36–37**** Day 36–37**** Day 36–37 Day 36–37****
6.6 ± 3.6 0.02 ± 0.02 1.1 ± 1.0 1.0 ± 1.4 3.9 ± 3.4 0.8 ± 0.6
Urinary albumin excretion
rate (mg/24hrs)
Day 7–8 Day 7–8**** Day 7–8**** Day 7–8**** Day 7–8** Day 7–8****
75.0 ± 28.6 0.04 ± 0.02 19.9 ± 18.1 12.6 ± 15.3 38.0 ± 22.7 19.1 ± 15.0
Day 36–37 Day 36–37**** Day 36–37**** Day 36–37**** Day 36–37*** Day 36–37****
23.1 ± 16.4 0.04 ± 0.04 2.1 ± 1.8 1.0 ± 11.4 6.4 ± 7.9 1.8 ± 2.9
Albumin creatinine ratio
(mg/mmol)
Day 36–37 Day 36–37*** Day 36-37*** Day 36–37***
4437 ± 2797 320.1 ± 120.3 312.3 ± 469.5 544.6 ± 302.2
Renin (pg/ml) Day 13 Day 13 Day 13**** Day 13**** Day 13 Day 13*
23296 ± 6579 15793 ± 3132 59849 ± 14187 62956 ± 20631 42021 ± 11893 43144 ± 9421
Day 42 Day 42 Day 42**** Day 42**** Day 42 Day 42
20972 ± 9578 19283 ± 47686 217021 ± 55210 297891 ± 130809 73480 ± 77856 114541 ± 72979
Table 1. A time course evaluation of morphological changes in the passive NTN model.
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exhibits persistence of features of human CKD until day
77 including albuminuria, ME, renal fibrosis, and renal
inflammation. The NTS-induced albuminuria has previ-
ously been demonstrated to be caused by podocyte
loss by nephrin IHC (data not published). However, the
observed continuous decline in the albumin concentra-
tion and the UAER on days 6–7 indicate that the albu-
minuria ameliorates over time. It has previously been
demonstrated that a glomerulus losing a limited part of
its podocytes, the protein leakage from that specific
glomerulus is ameliorated [13,14]. Moreover, a major
CKD hallmark is declined kidney function evaluated by
GFR, which was also observed in the NTN model but it
can also be caused by the significant ME that reduces
the peripheral capillary surface and the filtration sur-
face [15,16].
The histopathological evaluation showed similarities
to subtypes of glomerulonephritis (GN) including ME,
GBM thickening, inflammation, tubular casts, renal
fibrosis, iron and glomerular complement accumulation
[17–19]. Metaplasia describes the substitution with the
cuboidal epithelium lining Bowman’s capsule which is
believed to be more resistant to local changes in cyto-
kine or extracellular matrix components caused by pro-
teinuria [20,21]. The proliferation of glomerular and
tubular cells visualized by Ki-67, is also suggested to be
an adaptive response to cellular damage to reduce the
loss of filtered proteins [13]. The glomerular protein
leakage caused excessive tubular reabsorption resulting
in the tubular PAS-positive cytoplasmic vesicles. The
excessive reabsorption is hypothesized to lead to tubu-
lar degeneration and tubulointerstitial inflammation
and fibrosis. Moreover, the tubulointerstitial disease is
also believed to be caused by tubular iron accumula-
tion. Due to the glomerular protein leak, iron enters the
tubule lumen which previously has been shown to be
toxic to the renal tubule [22,23]. Characteristics like
glomerular and tubular proliferation, renal fibrosis and
iron deposition together with GFR decline were all
observed in varying degrees over time in the NTN
model suggesting qualitative similarities to CKD
in humans.
The improvement of the clinical and pathological
findings over time supports that the NTS induced a
reversible podocyte loss of the main part of all glomer-
uli because a more severe podocyte loss causes pro-
gressive glomerular injury without resolution. However,
not all glomeruli had recovered on day-77 supporting
the observation on day-42, that the NTS, besides ME,
also induced sclerotic and crescentic glomeruli as these
pathological changes unlikely would return to normal
functioning glomeruli again [24]. Therefore, the NTS-
induced kidney disease seemed to peak on most clin-
ical and histopathological parameters on day 42, where
after signs of improvements were observed, but patho-
logical changes consistent with chronic nephritis were
still present on day-77.
The clinical effect of inhibiting RAS showed that
both enalapril and losartan significantly improved the
kidney function by reducing the albuminuria, ACR, and
increasing the GFR. The histopathological evaluation
showed an effect on ME, as Ang II is believed to induce
proliferation of mesangial cells and increase the expres-
sion of extracellular matrix (ECM) proteins [25]. Both
enalapril and losartan reduced renal accumulation of
collagen III supporting the suggestion that locally pro-
duced Ang II by proximal tubular cells increases ECM
deposition [26]. Furthermore, enalapril and losartan
reduced the infiltration of CD45þ cells supporting the
suggestion that Ang II promotes immune activation
and recruitment of inflammatory cells [26,27]. An
important action of enalapril and losartan is that block-
ing of Ang II affects the local renal hemodynamic regu-
lation, which likely causes an indirect effect on
proteinuria, renal inflammation and fibrosis [25,28]. The
hemodynamic regulation is possibly caused by activa-
tion or upregulation of the protective RAS pathway that
includes ACE2 and its product Ang-(1–7) [29]. In experi-
mental models of renal diseases, Ang-(1–7) showed vas-
odilating, anti-inflammatory and anti-fibrotic effects
[30,31]. Both ACE-inhibitors and ARB’s have been dem-
onstrated to increase the circulating levels of Ang-(1–7)
in patients with hypertension and CKD. The increased
renin excretion, due to the negative feedback mechan-
ism caused by enalapril, causes an increased level of
Ang I, which can be converted into Ang-(1–7) by ACE2
and other endopeptidases. ARB’s increase the availabil-
ity of Ang II that can be converted into Ang-(1–7) by
ACE2 [31].
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In conclusion, the NTS causes glomerular damage
through the binding of antibodies to GBM and thereby
induces complement activation, glomerular damage
and GBM-thickening with ME. Moreover, significant
glomerular proliferation and development of tubular
casts, hyaline droplets together with infiltration of
inflammatory cells, renal fibrosis and iron accumulation
were also observed. The glomerular damage also
causes the clinical parameters; albuminuria and GFR
decline. Thus, the NTN model displayed acute and
chronic functional and morphological characteristics of
CKD. Finally, hallmarks of CKD including GFR, albumin-
uria, ACR, ME and fibrosis were improved by clinically
relevant treatments of CKD. Both enalapril and losartan
enhanced the kidney function of NTN-induced mice
demonstrating the relevance of the NTN model for
studying the pathogenesis of acute and chronic phases
of kidney disease and for identification of novel CKD
treatment strategies.
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Figure 5. Effect of inhibitors of the renin-angiotensin system on histopathology. (A) Scatter plot is showing the mean glomerular
mesangial expansion (ME) score. (B) Scatter plot is showing semi-quantification of collagen III positive area of the cortex area. (C)
Scatter plot is showing semi-quantification of the CD45 positive area of the cortex area. (D) Scatter plot is showing semi-quantifi-
cation of the C3d positive area of the cortex area. (E) Representative histopathological images. Data are shown as mean ± SD.p< .05, p< .01, p< .001, p< .0001 groups vs. vehicle group by one-way ANOVA using Tukey’s multiple comparisons
test or Kruskal–Wallis multiple testing (n¼ 10).
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